AXIM Biotechnologies, Inc., a leading player in the biotechnology sector, is headquartered in the United States. Founded in 2014, the company has made significant strides in the development of innovative cannabinoid-based products, focusing on areas such as pharmaceuticals, diagnostics, and consumer goods. AXIM is renowned for its unique offerings, including proprietary formulations that leverage the therapeutic potential of cannabinoids. The company’s commitment to research and development has positioned it as a pioneer in the industry, with notable achievements in clinical trials and product launches. With a strong market presence, AXIM Biotechnologies continues to drive advancements in cannabinoid science, aiming to improve health outcomes and enhance quality of life for patients worldwide.
How does AXIM Biotechnologies, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
AXIM Biotechnologies, Inc.'s score of 17 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
AXIM Biotechnologies, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi) or other industry standards. Given the lack of emissions data and formal climate commitments, AXIM Biotechnologies appears to be in the early stages of addressing its carbon footprint and climate impact. As the industry increasingly prioritises sustainability, it may be beneficial for the company to consider setting measurable targets and engaging in climate initiatives to align with best practices in environmental responsibility.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
AXIM Biotechnologies, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
